Cost-effectiveness of six months versus 1-year adjuvant trastuzumab in HER2 positive early breast cancer in Egypt

Journal article

Peer reviewed

Gihan Hamdy Elsisi, Yousery Nada, Noha Rashad, João Carapinha, Ahmad O. Noor, Diena M. Almasri, Mostafa Al Zaidy, Ahmed Foad and Hussien Khaled

Journal of medical economics, Vol.23(6), pp.575-580

02/06/2020

PMID: 32011199

Metrics

1 Record Views

Title: Cost-effectiveness of six months versus 1-year adjuvant trastuzumab in HER2 positive early breast cancer in Egypt
Creators - without role: Gihan Hamdy Elsisi - Future University in Egypt
Yousery Nada - Armed Forces College of Medicine
Noha Rashad - Armed Forces College of Medicine
João Carapinha - Northeastern University
Ahmad O. Noor - King Abdulaziz University
Diena M. Almasri - King Abdulaziz University
Mostafa Al Zaidy - Medical Oncology Department, Maadi Armed Forces Medical Compound, Oncology and Hematology Hospital, Cairo, Egypt
Ahmed Foad - Armed Forces College of Medicine
Hussien Khaled - Cairo University
Publication Details: Journal of medical economics, Vol.23(6), pp.575-580
Identifiers: 9934418708331
Academic Unit: King Abdulaziz University
Language: English
Resource Type: Journal article